Grifols Announces the Opening of Biotest Pharmaceuticals Corporation’s Newest Plasma Donor Center in Bowling Green, Ohio

Investing $1.5 million into local community; set to employ over 40 people from the local area; helping to save lives of patients around the world.

Bowling Green, Ohio (September 24, 2018) – Grifols is pleased to announce the opening of its newest Biotest Pharmaceuticals Corporation (BPC) plasma donor center located at 1616 East Wooster Street, Bowling Green, Ohio. The 13,000 square foot state-of-the-art facility officially opened its doors for business on September 17th, 2018 and brings the total number of BPC’s plasma collection centers to 23.

Ileana Carlisle, BPC’s Chief Executive Officer and President, said “We are pleased to have recently joined the Grifols Company, and look forward to being an active member of the Bowling Green community.   The opening of our 23rd plasma center is another step forward in our commitment to better serve the thousands of patients worldwide whose lives are enhanced through plasma-derived medicines.”

The total investment amounts to over $1.5 million in renovations of this newly constructed facility and expects to add over 40 jobs to the local economy.  Currently, there are employment opportunities available for medical personnel and phlebotomists.

In addition to supporting the local economy through employment, the Biomat USA Plasma Center is actively recruiting local residents to donate plasma and looking at ways to support the local community. Plasma donors contribute the much needed source material used in the manufacture of plasma-derived medicines and are also compensated for their commitment. Grifols operates the largest network of plasma donor centers in the world that includes over 200 centers in the United States.

To learn more about Grifols, this new BPC plasma center, and the difference we make in the lives of patients and the healthcare community, please visit and

About Grifols

Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.

Grifols’ three main divisions – Bioscience, Diagnostic and Hospital – develop, produce and market innovative products and services that are available in more than 100 countries.

With a network of approximately 250 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.

Grifols is headquartered in Barcelona, Spain and has 20,000 employees in 30 countries.

In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).